# Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults

> **NCT06988618** · — · RECRUITING · sponsor: **Galderma R&D** · enrollment: 600 (estimated)

## Conditions studied

- Prurigo Nodularis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06988618
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-11
- **Primary completion:** 2027-11-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06988618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06988618, "Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06988618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*